Physician profile
John Ferrante
NPI 1649269523
$1,342.25
in general payments reported to CMS, 2019-2025
19 companies · $203 in 2025
The $203 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.35 · 2020: $181 · 2021: $139 · 2022: $255 · 2023: $535 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $738.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $275.09 | 2021-2025 | |
| Avion Pharmaceuticals | $177.43 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $172.79 | 2022-2025 | Airsupra |
| Exact Sciences Corporation | $143.38 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Tolmar, INC. | $89.72 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $89.03 | 2022-2023 | Eliquis |
| Esperion Therapeutics, INC. | $45.22 | 2021-2023 | Nexletol |
| Shield Therapeutics INC | $45.09 | 2023 | Accrufer |
| Dermira, INC. | $43.37 | 2020 | |
| Astellas Pharma US INC | $42.26 | 2021 | |
| Novo Nordisk INC | $35.66 | 2023 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $28.35 | 2019 | |
| Abbvie INC. | $25.60 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $25.18 | 2021 | |
| Nestle Healthcare Nutrition INC. | $23.93 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $23.88 | 2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $20.03 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $19.25 | 2023 | Rexulti |
| Acerus Pharmaceuticals Corporation | $16.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ferrante listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.